Join
Live feed
·
PRReleasevia Quantisnow
Elevation Oncology Inc. logo

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

ByQuantisnow·Wall Street's wire, on your screen.
ELEV· Elevation Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELEV (Elevation Oncology Inc.) and more on Quantisnow.